BCM
ALNY icon

Bridgeway Capital Management’s Alnylam Pharmaceuticals ALNY Stock Holding History

Bridgeway Capital Management’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-5,990
Closed -$2.38M – 1230
2025
Q4 		$2.38M Sell
5,990
-40
-0.7% -$17.7K 0.05% 480
2025
Q3 		$2.75M Buy
+6,030
New +$2.46M 0.06% 443
2022
Q3 		– Sell
-14,100
Closed -$2.06M – 1407
2022
Q2 		$2.06M Sell
14,100
-13,600
-49% -$1.93M 0.05% 533
2022
Q1 		$4.52M Buy
+27,700
New +$4.22M 0.09% 360
2018
Q2 		– Sell
-54,000
Closed -$6.43M – 1410
2018
Q1 		$6.43M Buy
+54,000
New +$6.96M 0.07% 236

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bridgeway Capital Management's ALNY Position: Q1 2026 in Review

Bridgeway Capital Management sold out of Alnylam Pharmaceuticals (ALNY) in Q1 2026, closing a stake of 5,990 shares — an estimated $2.38M sold.

Bridgeway Capital Management first reported a position in ALNY in Q1 2018 and held it in 5 quarters. The position peaked at $6.43M in Q1 2018. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Bridgeway Capital Management reported no remaining Alnylam Pharmaceuticals position as of Q1 2026 after selling out during the quarter.
  • Bridgeway Capital Management sold 5,990 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $2.38M.
  • Bridgeway Capital Management first reported a position in Alnylam Pharmaceuticals in Q1 2018 and held it in 5 quarters.
  • Bridgeway Capital Management's Alnylam Pharmaceuticals position peaked at $6.43M in Q1 2018.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Bridgeway Capital Management's 13F filing for Q1 2026, filed 15 May 2026.